Pandemic Perspectives
One year on from the World Health Organization declaring COVID-19 a global pandemic on 11 March 2020, editors across Informa Pharma Intelligence publications are taking a closer look at its impact and possible lasting implications for the biopharma and medtech industries.
The COVID-19 pandemic has drawn an unusual level of public attention to the daily work processes and operations of the US Food and Drug Administration. But much of the work being spotlighted wasn’t “business as usual
A little over a year into the health emergency with the promise of multiple authorized vaccines making it possible for the country to almost visualize this crisis being in the rear-view mirror, there is increasing discussion of whether the FDA can and should replicate some of this speed or flexibility in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?